Japan – Eisai to Present the most recent Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

Eisai to Present the current Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

TOKYO, Mar 11, 2026 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) revealed today the business will provide the current findings on lecanemab (generic name, U.S. trademark name: LEQEMBI ®), Eisai’s anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s illness (ADVERTISEMENT), at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD ™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab information and extra research study findings from Eisai’s advertisement portfolio will be included in 6 discussions, consisting of 3 oral discussions. Eisai will host an industry-sponsored seminar.

Oral and Poster Presentations

Oral discussions will consist of the most recent findings from a United States real-world long-lasting treatment perseverance research study, and effectiveness and security results in apolipoprotein E ε4 (ApoEε4) homozygous providers in a U.S. multicenter real-world research study. In addition, four-year information from the Clarity advertisement Open-Label Extension trial in ApoEε4 non-carriers and heterozygotes, and a genome-wide association research study on unique hereditary variations connected with cognitive decrease in advertisement will exist as posters.

Eisai Symposium– Continue Life Their Way: Early Intervention in Alzheimer’s Disease

Eisai is sponsoring a seminar including 4 leading international specialists in the field of advertisement, on the subjects of why early intervention matters, continuing early advertisement treatment and real-world results. The seminar intends to improve understanding of the worth of early and continued anti-amyloid treatment in early advertisement by checking out how real-world proof can support positive client evaluation in medical practice, and how to acknowledge advertisement as a persistent condition that needs a multidisciplinary technique to care.

Eisai acts as the lead of lecanemab advancement and regulative submissions internationally with both Eisai and Biogen co-commercializing and co-promoting the item and Eisai having last decision-making authority.

AD/PD 2026 Presentations Relating to Eisai’s Key Compounds and Research
For more details, please go to: https://www.eisai.com/news/2026/pdf/enews202612pdf.pdf

Media Inquiries:

About Lecanemab (generic name, brand: Leqembi)

Lecanemab is the outcome of a tactical research study alliance in between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed versus aggregated soluble (protofibril) and insoluble types of amyloid-beta (Aβ).

Lecanemab has actually been authorized in 53 nations and areas consisting of Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulative evaluation in 6 nations. Following the preliminary stage with treatment every 2 weeks for 18 months, intravenous (IV) upkeep dosing with treatment every 4 weeks was authorized in 7 nations consisting of the U.S., China, the UK, and others, and applications have actually been submitted in 10 nations and areas. The U.S. FDA authorized Eisai’s Biologics License Application (BLA) for subcutaneous upkeep dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has actually been given Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable solution in Japan was sent. In January 2026, the Biologics License Application (BLA) for the subcutaneous solution was accepted in China. In December 2025, Lecanemab (IV) has actually been consisted of in the “Commercial Insurance Innovative Drug List”, just recently presented by the National Healthcare Security Administration (NHSA) of China.

Because July 2020 the Phase 3 medical research study (AHEAD 3-45) for people with preclinical advertisement, suggesting they are scientifically regular and have intermediate or raised levels of amyloid in their brains, is continuous. AHEAD 3-45 is carried out as a public-private collaboration in between the Alzheimer’s Clinical Trial Consortium that supplies the facilities for scholastic scientific trials in advertisement and associated dementias in the U.S, moneyed by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Considering that January 2022, the Tau NexGen scientific research study for Dominantly Inherited Advertisement (DIAD), that is performed by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is continuous and consists of lecanemab as the foundation anti-amyloid treatment.

About Protofibrils

Protofibrils are thought to add to the brain injury that accompanies advertisement and are thought about to be the most poisonous kind of soluble Aβ, having a main function in the cognitive decrease related to this progressive, devastating condition. 1st Protofibrils trigger injury to nerve cells in the brain, which in turn, can adversely affect cognitive function through numerous systems, not just increasing the advancement of insoluble Aβ plaques however likewise increasing direct damage to brain cell membranes and the connections that transfer signals in between afferent neuron or afferent neuron and other cells. It is thought the decrease of protofibrils might avoid the development of advertisement by decreasing damage to nerve cells in the brain and cognitive dysfunction. TWO

About the Collaboration in between Eisai and Biogen for advertisement

Eisai and Biogen have actually been teaming up on the joint advancement and commercialization of advertisement treatments given that 2014. Eisai works as the lead of LEQEMBI advancement and regulative submissions internationally with both business cocommercializing and co-promoting the item and Eisai having last decision-making authority.

About the Collaboration in between Eisai and BioArctic for advertisement

Because 2005, Eisai and BioArctic have actually had a long-lasting cooperation relating to the advancement and commercialization of advertisement treatments. Eisai got the worldwide rights to study, establish, make and market lecanemab for the treatment of advertisement pursuant to an arrangement with BioArctic in December 2007. The advancement and commercialization arrangement on the antibody lecanemab back-up was checked in May 2015.

Referrals
1. Amin L, Harris DA. Aβ receptors particularly acknowledge molecular functions shown by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12: 3451. doi:10.1038/ s41467-021-23507-z.
2. Ono K, Tsuji M. Protofibrils of Amyloid-β are essential Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020; 21( 3 ):952. doi: 10.3390/ ijms21030952. PMID: 32023927; PMCID: PMC7037706.